Caxton Associates (New York)’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-18,028
| Closed | -$201K | – | 484 |
|
|
2023
Q3 | $201K | Buy |
+18,028
| New | +$201K | 0.03% | 357 |
|
|
2022
Q3 | – | Sell |
-13,843
| Closed | -$654K | – | 508 |
|
|
2022
Q2 | $654K | Buy |
+13,843
| New | +$654K | 0.06% | 195 |
|
|
2018
Q4 | – | Sell |
-2,815
| Closed | -$241K | – | 321 |
|
|
2018
Q3 | $241K | Sell |
2,815
-496
| -15% | -$42.5K | 0.02% | 310 |
|
|
2018
Q2 | $384K | Hold |
3,311
| – | – | 0.02% | 240 |
|
|
2018
Q1 | $268K | Buy |
+3,311
| New | +$268K | 0.01% | 256 |
|